Determination of IgG Response Profile in SARS-CoV-2 Patients Using a Multiplex Serological Assay

Background: Beyond the diagnosis of SARS-CoV-2 infection, tools delivering a global picture patients’ humoral response may be interest for comprehension disease severity and assessment protection vaccination strategy. Objectives: Here we use commercial multiplex serological immunoassay CoViDiag®, based on an array five different antigens virus (the Nucleocapsid, Spike 1 2 subunits, RBD NTD domains Spike), to investigate profile IgG patients with recent infection depending outcome, or time post-PCR. Results: No cross-reaction was observed four other seasonal coronaviruses (100% specificity, 0/28). 100% (20/20) hospitalized PCR-positive presented detectable levels IgGs. 14 days post-PCR diagnosis, 92.3% patients, PCR-positive, that did not required hospitalization are presenting (36/39). Interestingly CoViDiag-positive samples, anti-RBD were found mainly in (85%, 17/20), while presence anti-S1 (60.9%, 28/46) combined absence (6.5%, 3/46) more characteristic nonhospitalized patients. Screening campaign group lacked both (18.2%, 4/22) (4.5%, 1/22). Conclusion: The CoViDiag® assay could used evaluate immunization improve their management.